Biogen Idec Inc. (Delaware)
Records under this name other than patents Biogen Idec Inc. (Delaware) holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Biogen Idec Inc. (Delaware)
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,682,734 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Ended no later than Jan 27, 2021 · From the USPTO record | Term ended | Ended no later than Jan 27, 2021 | From the USPTO record |
| US 6,399,061 | Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma Formerly held Term ended Term ended Jun 4, 2019 · From the USPTO record | Term ended | Term ended Jun 4, 2019 | From the USPTO record |
| US 5,736,137 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Term ended no later than Apr 7, 2018 · Low confidence | Term ended | Term ended no later than Apr 7, 2018 | Low confidence |
| US 5,776,456 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Term ended no later than Jul 7, 2018 · Low confidence | Term ended | Term ended no later than Jul 7, 2018 | Low confidence |
| US 5,843,439 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Term ended no later than Dec 1, 2018 · Low confidence | Term ended | Term ended no later than Dec 1, 2018 | Low confidence |